Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Diabetes Management posted higher revenue and profit, driven by strong sales mainly in Europe, increased revenue in emerging markets, the positive impact of exchange rates, cost reductions from structural reforms, and improved profitability following the transfer of the CGM business. Healthcare Solutions posted lower revenue and profit due to a decline in electronic medical record sales caused by server supply shortages and temporary expenses. Diagnostics and Life Science posted higher revenue and profit, supported by price revisions, selling, general and administrative expense reductions, US tariff refunds and the positive impact of exchange rates.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥179,970 million (YoY +3.8%) |
| Operating profit | ¥19,439 million (YoY +87.3%) |
| Ordinary income | ¥17,007 million |
| Profit attributable to owners of the parent | ¥13,313 million |
| Net income per share | ¥104.94 |
| Equity ratio | End of the current fiscal period 32.1 / End of previous period 29.8 |
| Total assets | ¥528,429 million |
| Net assets | ¥168,627 million |
| Cash flows from operating activities | ¥21,184 million |
| Cash flows from investing activities | ¥-5,012 million |
| Cash flows from financing activities | ¥-16,734 million |
| Cash and cash equivalents at end of period | ¥37,777 million |
| Full-year earnings forecast | Net Sales ¥366,000 million (YoY +0.4%) / Operating profit ¥33,000 million (YoY +45.5%) / Ordinary income ¥26,700 million (YoY +317.8%) / Net income ¥18,000 million |
| Revision to Earnings Forecast | Net Sales ¥359,700 million → ¥366,000 million（+1.8%） / Operating profit ¥27,000 million → ¥33,000 million（+22.2%） / Ordinary income ¥22,000 million → ¥26,700 million（+21.4%） / Net income ¥15,400 million → ¥18,000 million（+16.9%） |
| Annual Dividend Forecast | ¥42 → ¥42（0.0%） |
| Segment revenue | Diabetes management ¥54,655 million (YoY +12.3%), Healthcare solutions ¥59,550 million (YoY -5.0%), Diagnostics and life sciences ¥65,681 million (YoY +6.0%) |
| Segment profit | Diabetes management ¥18,565 million (YoY +99.0%), Healthcare solutions ¥459 million (YoY -84.5%), Diagnostics and life sciences ¥4,292 million (YoY +153.5%) |
| Regional sales | ¥70,811 million, ¥47,926 million, ¥38,069 million, ¥23,162 million |
| Depreciation and amortization | ¥13,256 million |
| Impairment loss | ¥-28 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Not disclosed |
| Issued Shares at Period-End | 127,327,581 Shares |
| Treasury Shares at Period-End | 212,023 Shares |
| Factors Behind Changes in Business Performance | Diabetes Management posted higher revenue and profit, driven by strong sales mainly in Europe, increased revenue in emerging markets, the positive impact of exchange rates, cost reductions from structural reforms, and improved profitability following the transfer of the CGM business. Healthcare Solutions posted lower revenue and profit due to a decline in electronic medical record sales caused by server supply shortages and temporary expenses. Diagnostics and Life Science posted higher revenue and profit, supported by price revisions, selling, general and administrative expense reductions, US tariff refunds and the positive impact of exchange rates. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The upward revision to the full-year forecasts reflects the positive impact of the change in exchange rates, strong first-half performance and higher-than-expected profitability in Diabetes Management, cost reductions, and the impact of US tariff refunds and selling, general and administrative expense reductions in Diagnostics and Life Science. In Healthcare Solutions, the forecasts incorporate a decline in electronic medical record revenue due to server supply shortages.